Zenas BioPharma
ZBIO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +343.3% in FY2025
Leon O. Moulder, Jr. is the CEO of Zenas BioPharma and was paid $4.7M in FY2025 (Dec), down 77%.
Pay$100 in the stock at the end of FY24 → $443
Executives3
See all- 1Leon O. Moulder, Jr.Founder, Chief Executive Officer and ChairmanFY2025
- 2Lisa von Moltke, M.D.Head of Research and Development and Chief Medical OfficerFY2025
- 3Joseph L. FarmerPresident and Chief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allZenas BioPharma paid its 3 named executives $10.7M in total in FY2025 (Dec). CEO Leon O. Moulder, Jr. was paid $4.7M of that.
| Name | |||
|---|---|---|---|
| Leon O. Moulder, Jr.Founder, Chief Executive Officer and Chairman | |||
| Lisa von Moltke, M.D.Head of Research and Development and Chief Medical Officer | Not disclosed | Not disclosed | |
| Joseph L. FarmerPresident and Chief Operating Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Zenas BioPharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- John Orloff, M.D.Director · 3 yr on the boardIndependentCompensation (Chair), Science and Technology (Chair)—Paid as an executive
- Patricia AllenDirector · 1 yr on the boardIndependentAudit (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings4
See all| Annual report | 10-K | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 11, 2025 | FY2024 |
